Fezolinetant

🧮 Dose calculator

Menopausal vasomotor symptoms · Regimen source: FDA Veozah · 2.1

• • Liver tests before starting; do not start if ALT or AST ≥2× ULN or bilirubin ≥2× ULN. Monitor monthly for 3 months, then at 6 and 9 months. Swallow whole. FDA Veozah · 2.1FDA Veozah · Boxed Warning

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Veozah · 8.1

  “Risk Summary There are no data on VEOZAH use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Veozah · 8.2

  “Risk Summary There are no data on the presence of fezolinetant in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Veozah · 8.4

  “The efficacy and safety of VEOZAH in individuals less than 18 years of age have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Veozah · 8.5

  “There have not been sufficient numbers of geriatric women involved in clinical trials utilizing VEOZAH to determine whether those over 65 years of age differ from younger women in their response to VEOZAH.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.